Moon Shots Program

There are those who stand together to make a difference in the fight against cancer — The University of Texas MD Anderson Cancer Center’s community of donors. From across the world and all walks of life, these diverse supporters are united in their generosity toward the Moon Shots Program, the most ambitious assault on cancer ever undertaken by a single institution.

Christopher Logothetis, M.D., chair and professor, Genitourinary Medical Oncology at MD Anderson Cancer Center, details progress made in the first year of the Prostate Cancer Moon Shot.

Christopher Logothetis, M.D., chair and professor, Genitourinary Medical Oncology at MD Anderson Cancer Center, details progress made in the first year of the Prostate Cancer Moon Shot.

Jeffrey Gershenwald, M.D., professor in MD Anderson Cancer Center’s Surgical Oncology department, details progress made in the first year of the Melanoma Moon Shot.

Jeffrey Gershenwald, M.D., professor in MD Anderson Cancer Center’s Surgical Oncology department, details progress made in the first year of the Melanoma Moon Shot.

John Heymach, M.D., associate professor in MD Anderson Cancer Center's Thoracic/Head & Neck Medical Oncology department, details progress made in the first year of the Lung Cancer Moon Shot.

John Heymach, M.D., associate professor in MD Anderson Cancer Center's Thoracic/Head & Neck Medical Oncology department, details progress made in the first year of the Lung Cancer Moon Shot.

Michael Keating, M.D., professor in MD Anderson Cancer Center's Leukemia department, details progress made in the first year of the CLL Moon Shot.

Michael Keating, M.D., professor in MD Anderson Cancer Center's Leukemia department, details progress made in the first year of the CLL Moon Shot.

Anil Sood, M.D., professor, Gynecologic Oncology and Reproductive Medicine at MD Anderson Cancer Center, details progress made in the first year of the Breast and Ovarian Cancers Moon Shot.

Anil Sood, M.D., professor, Gynecologic Oncology and Reproductive Medicine at MD Anderson Cancer Center, details progress made in the first year of the Breast and Ovarian Cancers Moon Shot.

Guillermo Garcia-Manero, M.D., professor in MD Anderson Cancer Center’s Leukemia department, details progress made in the first year of the AML/MDS Moon Shot.

Guillermo Garcia-Manero, M.D., professor in MD Anderson Cancer Center’s Leukemia department, details progress made in the first year of the AML/MDS Moon Shot.

Myelodysplastic syndrome (MDS) survivor Holly Easley Holly was one of many patients present at the moon shots announcement press conference and she shares her thoughts on this and her journey. For more information visit http://cancermoonshots.org.

Myelodysplastic syndrome (MDS) survivor Holly Easley Holly was one of many patients present at the moon shots announcement press conference and she shares her thoughts on this and her journey. For more information visit http://cancermoonshots.org.

Chronic lymphocytic leukemia (CLL) patient Harry Moore Harry was one of many patients present at the moon shots announcement press conference and he shares his thoughts about what he heard. For more information visit http://cancermoonshots.org.

Chronic lymphocytic leukemia (CLL) patient Harry Moore Harry was one of many patients present at the moon shots announcement press conference and he shares his thoughts about what he heard. For more information visit http://cancermoonshots.org.

Melanoma patient Steve Martin Steve was one of many patients present at the moon shots announcement press conference and he shares his thoughts in that and his hope for the future. For more information visit http://cancermoonshots.org.

Melanoma patient Steve Martin Steve was one of many patients present at the moon shots announcement press conference and he shares his thoughts in that and his hope for the future. For more information visit http://cancermoonshots.org.

Breast cancer survivor Rachel Midgett Rachel was one of many patients in attendance at the moon shots announcement press conference and she shares her story and thoughts on the bold program. For more information visit http://cancermoonshots.org.

Breast cancer survivor Rachel Midgett Rachel was one of many patients in attendance at the moon shots announcement press conference and she shares her story and thoughts on the bold program. For more information visit http://cancermoonshots.org.

The University of Texas MD Anderson Cancer Center on Sept. 21, 2012, announced the launch of the Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths.

The University of Texas MD Anderson Cancer Center on Sept. 21, 2012, announced the launch of the Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths.

The University of Texas MD Anderson Cancer Center announces the launch of the Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths.

The University of Texas MD Anderson Cancer Center announces the launch of the Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths.

Inspired by America’s drive a generation ago to put a man on the moon, MD Anderson’s Moon Shots Program is a highly-concentrated effort to rapidly and dramatically decrease suffering and death in several major cancers, including acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS); chronic lymphocytic leukemia (CLL); lung; melanoma; prostate and two cancers linked at the molecular level: triple-negative breast and ovarian. Focused teams are building on new technology and scientific knowledge that has rapidly expanded in recent years. What is learned with the first moon shot cancers will advance knowledge for all others. Ronald DePinho, M.D., president of The University of Texas MD Anderson Cancer Center, shares more about this program that’s unprecedented in scope and ambition for a single institution.